Mohammed Rasool

Dr. Mohammed Rasool

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2026 in Molecules
Verified
Journal Article
Open access
PDF file
WAWaleed Khaled Younis Albahadly
Waleed Khaled Younis Albahadly
HAHaider Al-Saedi
Haider Al-Saedi
JAJamal Ali Ashoor
Jamal Ali Ashoor
MRMohammed Rasool
Mohammed Rasool
SHSamer Ali Hasan
Samer Ali Hasan
MAMeeqaat H. Altrufi
Meeqaat H. Altrufi
Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by excessive keratinocyte proliferation, oxidative stress, and dysregulated cytokine signaling. Although topical corticosteroids remain the first-line therapy, their long-term use is often limited by adverse effects, highlighting the need for safer non-steroidal therapeutic alternatives. This study investigated the therapeutic efficacy and underlying mechanisms of a topical astaxanthin (AST) formulation in an imiquimod (IMQ)-induced mouse model of psoriasiform dermatitis. Following IMQ induction, mice were randomly assigned to vehicle, clobetasol, or AST treatment groups (0.5–1.5%) for 14 days. Disease progression was evaluated through biochemical analysis of oxidative stress biomarkers, including NADPH oxidase (NOX), malondialdehyde (MDA), nitric oxide (NO), and superoxide dismutase (SOD), as well as ELISA-based quantification of inflammatory cytokines (TNF-α, IL-6, IL-17, and IL-23). Histopathological changes were assessed using hematoxylin and eosin staining, while molecular alterations were examined by RT-qPCR analysis of psoriasis-associated keratin genes (Krt16, Krt17, and Krt6a) and evaluation of JAK–STAT signaling activity. AST treatment significantly suppressed the IL-23/IL-17 inflammatory axis, reduced NOX activity and lipid peroxidation, restored endogenous antioxidant defenses, and inhibited JAK–STAT signaling. These biochemical and molecular effects were accompanied by marked downregulation of keratin gene expression and substantial histological improvement, including normalization of epidermal thickness, reduced parakeratosis, and decreased inflammatory infiltration. Notably, high-dose AST demonstrated therapeutic efficacy comparable to, and in some parameters exceeding, that of clobetasol. Collectively, these findings indicate that topical astaxanthin exerts coordinated antioxidant, anti-inflammatory, and anti-proliferative effects, supporting its potential as a promising multi-target non-steroidal therapeutic candidate for psoriasis management.

10 August 2026 in Cells
Verified
Journal Article
Open access
PDF file
WAWaleed Khaled Younis Albahadly
Waleed Khaled Younis Albahadly
MRMohammed Rasool
Mohammed Rasool
HAHaider Al-Saedi
Haider Al-Saedi
ZAZahraa Abed Al-Kareem
Zahraa Abed Al-Kareem
SHSamer Ali Hasan
Samer Ali Hasan
MAMeeqaat H. Altrufi
Meeqaat H. Altrufi
Background: Cisplatin is a widely used chemotherapeutic agent whose clinical application is often limited by severe hepatorenal toxicity associated with oxidative stress and cellular injury. Nicotinamide riboside (NR), a natural precursor of nicotinamide adenine dinucleotide (NAD+), has emerged as a promising cytoprotective compound with antioxidant and metabolic regulatory properties. This study investigated the protective effects of NR against cisplatin-induced hepatorenal toxicity and explored its potential mechanisms of action. Methods: Thirty-six adult male Wistar rats were randomly assigned to four groups (n = 6): control, cisplatin (7 mg/kg, i.p.), nicotinamide riboside (50 mg/kg/day, orally), and cisplatin plus NR. Renal and hepatic function biomarkers, lipid profile parameters, oxidative stress markers, and antioxidant status were evaluated. Relative mRNA expression of Nrf2 and NQO1 was determined using RT-qPCR. Histopathological examinations of liver and kidney tissues were also performed. Results: Cisplatin administration induced marked hepatorenal injury, evidenced by significant elevations in serum KIM-1 (395.27 vs. 116.04 ng/mL), urea (71.16 vs. 21.33 mg/dL), creatinine (3.49 vs. 0.26 mg/dL), AST (325.83 vs. 95.16 U/L), and ALT (102.83 vs. 45.50 U/L), accompanied by dyslipidemia, oxidative stress, and severe histopathological alterations. NR treatment significantly attenuated these changes, reducing KIM-1, urea, creatinine, AST, and ALT by 55.5%, 47.8%, 48.1%, 55.4%, and 33.5%, respectively, compared with the cisplatin group. NR also improved antioxidant status by increasing GSH and SOD levels while reducing MDA and NO concentrations. Hepatic NAD+ levels and the NAD+/NADH ratio were significantly decreased by cisplatin and significantly restored by NR treatment. In addition, NR significantly upregulated the relative mRNA expression of Nrf2 and NQO1 and markedly preserved hepatic and renal histological architecture. Pharmacological inhibition of Nrf2 with ML385 significantly attenuated these protective effects of NR across biochemical, lipid, and oxidative stress parameters, confirming that they are, at least in part, Nrf2-dependent. Conclusions: Nicotinamide riboside exerts protective effects against cisplatin-induced hepatorenal toxicity that are mechanistically linked to activation of the Nrf2/NQO1 antioxidant pathway and restoration of hepatic NAD+ homeostasis. This finding supports the potential of NR as an adjunctive strategy for mitigating cisplatin-associated hepatorenal injury and warrants further preclinical and clinical investigation.

31 December 2025 in Karbala Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
BSBaneen Hadi Saeed
Baneen Hadi Saeed
MRMohammed Rasool
Mohammed Rasool
Background: Diabetes is a prevalent, life-threatening chronic disease and one of the leading causes of death worldwide. sodium glucose co-transporter 2, is the major co-transporter involved in renal glucose uptake, and its inhibition has been shown to be a relatively new strategy for managing diabetes. The gene encoding sodium glucose co-transporter 2 is located on chromosome 16 and is also known as soluble carrier family 5 member 2. Empagliflozin is a relatively new agent that improves glycemic control by increasing glucose excretion and inhibiting sodium–glucose cotransporter 2. The aim of study: was to investigate the potential effects of common single nucleotide polymorphisms in the sodium–glucose cotransporter 2 encoding gene soluble carrier family 5 member 2 on diabetes-related metabolic characteristics in patients who are at risk of type 2 diabetes. Secondly, we investigated whether these single nucleotide polymorphisms have pharmacogenetic significance by potentially influencing the response of type 2 patients to empagliflozin treatment. Methodology: The study participants included 50 healthy subjects and 110 diabetics who were selected during outpatient clinic visits with age range 30 to 65 years. Each subject underwent glycemic analysis, renal parameters, and genetic analysis of the soluble carrier family 5-member 2 reference SNP 121918621 polymorphism with blood samples that collected from different cities of Iraq. Each patient received 10 mg oral tablet of empagliflozin daily as monotherapy. Results: The findings of the study revealed significant variability with P-value less 0.05 in each of the glycemic and renal parameters among the study groups, with diabetic patients having significantly higher glycemic and renal parameters than healthy samples. soluble carrier family 5 member 2 reference SNP 121918621genotype distribution showed that (Fasting Serum Insulin, Fasting blood glucose, Glycated hemoglobin) levels did not differ significantly. The results also showed significant differences in (Serum creatinine, blood Urea) levels. Conclusion: The soluble carrier family 5-member 2 polymorphism is one of the genetic variables that contribute to heterogeneity in empagliflozin responsiveness in people with type 2 diabetes.

23 January 2026 in Archives of Breast Cancer
Verified
Journal Article
Open access
PDF file
LALabib Al-Musawe
Labib Al-Musawe
MRMohammed Rasool
Mohammed Rasool
INIman Hussein Naser
Iman Hussein Naser
Background: Breast cancer is a leading cause of death among Iraqi women, necessitating studies on its demographic and clinical factors to guide diagnosis and treatment approaches. This study aimed to identify the demographic and clinical characteristics of a sample of Iraqi women with breast cancer and predictors of therapy receipt. Methods: A cross-sectional study was conducted in Karbala Province, Iraq, from October 2024 to February 2025 at the Al-Husseini Medical City Oncology Department. Data on age, marital status, employment, residence, menopausal status, family history, disease stage, treatment, and receptor involvement were collected. The χ2 test was used to compare the metastatic and nonmetastatic groups. Multinomial logistic regression was used to identify predictors of therapy receipt. Results: Of 1737 recorded cancer cases in Karbala Province, 342 (19.7%) were diagnosed as breast cancer. Among these, 152 cases (44.4%) met the inclusion criteria. Most cases were nonmetastatic (n = 123; 80.9%), estrogen receptor–positive, progesterone receptor–positive, and underwent surgery and chemotherapy. Family history (odds ratio [OR], 2.75; 95% CI, 1.00–7.54), stage I disease (OR, 4.05; 95% CI, 3.72–4.41), stage II disease (OR, 3.13; 95% CI, 1.91–5.12), stage III disease (OR, 3.56; 95% CI, 2.18–4.66), radiation therapy (OR, 0.02; 95% CI, 0.001–0.55), chemotherapy (OR, 0.15; 95% CI, 0.05–0.50), and targeted therapy (trastuzumab) (OR, 0.03; 95% CI, 0.01–0.18) were associated with hormonal therapy. Being menopausal (OR, 0.08; 95% CI, 0.01–0.60), having human epidermal growth factor receptor 2 (HER2)–positive status (OR, 5.34; 95% CI, 1.51–18.89), and receiving hormonal therapy (OR, 0.02; 95% CI, 0.002–0.18) were associated with targeted therapy (trastuzumab). Conclusion: The findings of this study show that breast cancer treatment decisions—especially for hormonal and targeted therapies—are linked to clinical factors such as hormone receptor status, HER2 involvement, disease stage, and menopausal status.

31 January 2025 in Wiadomości Lekarskie
Verified
Journal Article
Closed access
FAFarah Ali Alquraishi
Farah Ali Alquraishi
MRMohammed Rasool
Mohammed Rasool
Aim: Background: Lifelong exogenous insulin is cornerstone of treatment type 1 diabetes mellitus (T1DM). The efficacy of insulin in achieving glycemic control depends on its binding affinity to the insulin receptor (INSR). Insulin sensitivity can be influenced by various factors, including genetic polymorphisms. Single nucleotide polymorphisms (SNPs) in the INSR gene may affect the efficacy of exogenous insulin in achieving glycemic control in T1DM, potentially leading to insulin resistance. Genetic mapping of the INSR gene aims to identify the precise loci of SNPs, offering deeper insights into the diminished therapeutic response. Aims: this cross-sectional pharmacokinetic study is of significant interest, as it presents innovative approaches in precision medicine. Novel applications of genome engineering technologies for targeted gene corrections may have substantial therapeutic implications.Material and methods: Method: The effect of the SNP rs2229429 G>A have been investigated in 99 T1D individuals, with a mean age of 12.3 years. These patients were managed with exogenous insulin through a basal-bolus monotherapy regimen. Genotyping was performed using an allele-specific polymerase chain reaction technique, and the data were statistically analyzed.Results: Results: Results revealed the prevalence of the minor allele frequency is 12% in a sample of Iraqi population. Homozygous mutant carriers of rs2229429 G>A were 10.479 times at higher risk for developing poor glycemic control (HbA1c >86 mmol/mol) compared to wild genotype in T1DM (p=0.008). Ultimately poor responders to exogenous insulin, demonstrating significantly higher plasma insulin receptors levels (p<0.001).Conclusions: Conclusion: The investigated SNP is firmly correlated with hyperglycemia in T1DM and contributes to the development of double diabetes.